Penumbra Inc
PEN
Company Profile
Business description
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Contact
One Penumbra Place
AlamedaCA94502
USAT: +1 510 748-3200
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
4,500
Stocks News & Analysis
stocks
Chart of the Week: Software selloff creates opportunity for these two stocks
Can AI disrupt the software business model?
stocks
Market is misinterpreting AI impact on cheap ASX share
Unwarranted sell-off with shares down by half in three months.
stocks
AI is a tailwind for beaten down ASX tech share
Latest earnings report outlines cost reduction potential of AI.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,411.20 | 24.90 | -0.26% |
| CAC 40 | 8,559.07 | 39.86 | 0.47% |
| DAX 40 | 25,175.94 | 189.69 | 0.76% |
| Dow JONES (US) | 49,482.15 | 307.65 | 0.63% |
| FTSE 100 | 10,806.41 | 125.82 | 1.18% |
| HKSE | 26,906.62 | 140.90 | 0.53% |
| NASDAQ | 23,152.08 | 288.39 | 1.26% |
| Nikkei 225 | 58,853.23 | 270.11 | 0.46% |
| NZX 50 Index | 13,595.79 | 70.21 | 0.52% |
| S&P 500 | 6,946.13 | 56.06 | 0.81% |
| S&P/ASX 200 | 9,174.90 | 28.00 | -0.30% |
| SSE Composite Index | 4,141.31 | 5.92 | -0.14% |